• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncCrabb.pdf
    Size:
    82.50Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Crabb, S.
    Plummer, R.
    Greystoke, A.
    Carter, Louise
    Pacey, S.
    Walter, H.
    Coyle, V. M.
    Knurowski, T.
    Clegg, K.
    Ashby, F.
    Pegg, N.
    West, W.
    Brooks, N.
    Hughes, A.
    de Bono, J.
    Show allShow less
    Affiliation
    University Hospital Southampton, NHS Foundation Trust, Southampton, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background CCS1477 is a potent, selective, orally bioavailable inhibitor of the bromodomains of p300 and CBP, two closely related histone acetyl transferases with oncogenic roles in cancer. In vitro and in vivo models demonstrate molecular alterations that increase sensitivity to p300/CBP inhibition with CCS1477. Tumours with loss of function mutations in either p300 or CBP become dependent on the corresponding non-mutated paralogue (twin) protein. When the non-mutated twin is inhibited, this drives synthetic lethality leading to apoptosis/cell death. Recently, loss of function mutations in ARID1A have also demonstrated functional dependence upon p300/CBP. Trial design This Ph I/IIa study sponsored by CellCentric, evaluates the clinical activity of CCS1477 in patients with advanced solid tumours harbouring molecular alterations indicating sensitivity to p300/CBP inhibition. Specifically, potential markers determined by local testing, include loss of function mutations in p300, CBP or ARID1A; myc and AR amplification or over expression. Acceptable tests are next generation sequencing or equivalent, in archival or fresh tumour biopsies or in cell free DNA from a pre treatment blood sample. IHC may be used for over expression of proteins such as myc or AR. Patients with cancers where there is strong molecular rationale for a potential response to CCS1477 (e.g. myc over expression in Small Cell Lung Cancer and Radiation induced breast sarcoma) may be entered following discussion with sponsor. The trial is in 2 parts. Part 1 commenced Dec 2020 in the UK, and is opening in US & EU mid 2021, recruiting 20 patients to receive CCS1477 at a dose and schedule previously declared tolerated from the rising dose tolerability arm of the trial being separately conducted in men with metastatic castrate resistant prostate cancer (NCT03568656). In Part 2, up to 30 patients will receive CCS1477 at the recommended phase 2 dose and schedule. Anti-tumour activity will be determined by standard imaging according to RECIST guidelines. Paired tumour biopsies for biomarker assessment are being collected.
    Citation
    Crabb S, Plummer R, Greystoke A, Carter L, Pacey S, Walter H, et al. 560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S617.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624709
    DOI
    10.1016/j.annonc.2021.08.1082
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.1082
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.1082
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.